𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

✍ Scribed by Yoo, Dae Hyun (author);Hrycaj, Pawel (author);Miranda, Pedro (author);Ramiterre, Edgar (author);Piotrowski, Mariusz (author);Shevchuk, Sergii (author);Kovalenko, Volodymyr (author);Prodanovic, Nenad (author);Abello-Banfi, Mauricio (author);Gutierrez-Ureña, Sergio (author);Morales-Olazabal, Luis (author);Tee, Michael (author);Jimenez, Renato (author);Zamani, Omid (author);Lee, Sang Joon (author);Kim, Ho Ung (author);Park, Won (author);Müller-Ladner, Ulf (author)

Book ID
125843521
Publisher
BMJ Publishing Group
Year
2013
Tongue
English
Weight
823 KB
Volume
72
Category
Article
ISSN
0003-4967

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomised, double-blind, parallel-gro
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
✍ Yoo, Dae Hyun (author);Hrycaj, Pawel (author);Miranda, Pedro (author);Ramiterre, 📂 Article 📅 2013 🏛 BMJ Publishing Group 🌐 English ⚖ 823 KB

Objectives To compare the efficacy and safety of innovator infliximab (INX) and CT-P13, an INX biosimilar, in active rheumatoid arthritis patients with inadequate response to methotrexate (MTX) treatment. Methods Phase III randomised, double-blind, multicentre, multinational, parallel-group study. P